Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

sults, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

  • our ability to borrow additional amounts under the loan agreement, which is subject to the discretion of the Lender;
  • our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan by the September 14, 2009 maturity date;
  • our ability to control our operating expenses;
  • our failure to timely recruit and enroll patients for the FDG-PET clinical trial, as well as any future clinical trial;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays;

  • '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...  regulated information — Global biopharmaceutical company UCB, Inc. ... the launch of a new Pledge campaign for people ... Pledge empowers the millions of Americans living ... personal commitment to demand more: greater understanding of the ... additional partial-onset seizure control.  More information is available at ...
(Date:6/18/2013)... The "Bioinformatics Market By Sector (Molecular Medicine, ... & Data Analysis Services) & Application (Genomics, Proteomics & Drug ... Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and an ...
(Date:6/18/2013)... This webinar will examine the history ... and review the basic FDA regulations and guiding ... these principles through real world case studies and ... on FDA regulations and guidance related to prescription ... traditional and newer forms of promotional materials for ...
(Date:6/18/2013)... , June 18, 2013   Lexicon ... a biopharmaceutical company focused on discovering breakthrough treatments ... Northcott has joined the company as its ... Mr. Northcott brings extensive commercial experience to Lexicon, ... a variety of therapeutic areas. Mr. ...
Breaking Biology Technology:Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... 25 Celator Pharmaceuticals today announced that Scott Jackson, chief ... Piper Jaffray Health Care Conference in New York and the ... provide a corporate overview and an update on the company,s ... follows: , , ...
... 25 AngioGenex, Inc. (OTC Bulletin Board: AGGX) is a ... and proteins for the discovery and development of anti-angiogenic drugs ... 2008 objectives and its key business goals for 2009. , ... of important milestones that it set for itself in 2008. ...
... today announced that data from its phase 1/2 clinical ... highlighted in an oral presentation at the 50th Annual ... San Francisco, California, on December 9, 2008. , ... the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin ...
Cached Biology Technology:Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference 2AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 2AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 3Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3
(Date:6/17/2013)... the concept of improving original foundations with more modern ... University of Pittsburgh,s Kenneth P. Dietrich School of Arts ... could make drug delivery, gas storage, and gas transport ... were reported in the latest issue of the ... ). , The recent work builds upon Pitt Associate ...
(Date:6/17/2013)... SAN FRANCISCO-- Vitamin D supplementation may help delay early ... finds. The results were presented Monday at The Endocrine ... girls, puberty generally begins between the ages of 10 ... 12 to 16 years of age. Precocious puberty is ... age of 8; in boys, it is diagnosed when ...
(Date:6/17/2013)... State University research associate has received a prestigious fellowship ... prevent the spread of malaria. , Bart Bryant, research ... Health,s National Research Service Award Individual Postdoctoral Fellowship, which ... Kansas State University researcher to receive the award and ... such an award. , Bryant, a university doctoral graduate ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Vitamin D supplementation may delay precocious puberty in girls 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... DALLAS May 11, 2010 Microbiologists at UT Southwestern ... a potential target in cattle that could be exploited to ... strain of Escherichia coli . In the ... Proceedings of the National Academy of Sciences , researchers ...
... is not the only vehicle that can be propelled electrically. ... Mikel Lejarza, Jose Ignacio Uriarte, Miguel ngel Gmez Solaetxe and ... on an innovative project: to have a sailing boat that ... electric energy obtained from the movement of the wind in ...
... 2010) -- Cell-cell junctions are multi-molecular complexes that ... as barriers to permeability, and allow intercellular transport. ... Spring Harbor Laboratory Press, surveys current research on cell ... University) and W. James Nelson (Stanford University), both leaders ...
Cached Biology News:UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle 2Project for sailing vessels to maneuver in ports using electric energy from wind 2Project for sailing vessels to maneuver in ports using electric energy from wind 3
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
... samples may be carried out using this high ... System control and data processing is provided by ... elegant, powerful and very easy to use software ... 2000., The supplied detector is the ground breaking ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
... to MSY2/YBOX2 ( Abpromise for ... Antigen: Synthetic peptide derived from ... of human YBX2. (Note: the ... Entrez ...
Biology Products: